Regeneron Pharmaceuticals Aktie
WKN: 881535 / ISIN: US75886F1075
| 15.06.2025 18:25:27 | 
Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment
(RTTNews) - Sanofi (SNYNF, SNY) and Regeneron Pharmaceuticals Inc. (REGN) presented positive results from the EVEREST Phase 4 study involving adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) across all primary and secondary efficacy endpoints related to CRSwNP, as well as all asthma-related endpoint.
The results reinforce Dupixent's efficacy in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13—two key drivers of type 2 inflammation.
The companies noted that the safety results in the EVEREST study were generally consistent with the known safety profile of Dupixent in its approved respiratory indications, with similar overall rates of adverse events (AEs) observed between Dupixent (64%) and omalizumab (67%). Serious AEs were reported in 2% and 4% of patients treated with Dupixent and omalizumab, respectively. Additionally, AEs leading to study discontinuation were reported in 3% of Dupixent patients and 1% of omalizumab patients.
For More Such Health News, visit rttnews.com.
 Der finanzen.at Ratgeber für Aktien!
						
						
						
							
								Der finanzen.at Ratgeber für Aktien!
							
							Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
| 29.10.25 | NASDAQ Composite Index-Wert Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte ein Investment in Regeneron Pharmaceuticals von vor 10 Jahren abgeworfen (finanzen.at) | |
| 28.10.25 | Pluszeichen in New York: S&P 500 beendet die Sitzung weit in der Gewinnzone (finanzen.at) | |
| 28.10.25 | Gewinne in New York: NASDAQ Composite beendet den Handel mit Gewinnen (finanzen.at) | |
| 28.10.25 | NASDAQ 100-Handel aktuell: Zum Ende des Dienstagshandels Gewinne im NASDAQ 100 (finanzen.at) | |
| 28.10.25 | Börse New York in Grün: NASDAQ Composite stärker (finanzen.at) | |
| 28.10.25 | S&P 500 aktuell: Das macht der S&P 500 am Dienstagnachmittag (finanzen.at) | |
| 28.10.25 | Optimismus in New York: So steht der NASDAQ 100 am Nachmittag (finanzen.at) | |
| 28.10.25 | Starker Wochentag in New York: S&P 500 verbucht am Dienstagmittag Zuschläge (finanzen.at) | 
Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
| Regeneron Pharmaceuticals Inc. | 563,00 | -0,42% |  | 
| Sanofi S.A. (spons. ADRs) | 43,40 | -0,46% |  | 
| Sanofi S.A. | 87,60 | -0,88% |  | 
 
									 
									 
								